| Homepage | Forward to a Friend | Make a Donation |
 |
| eLetter #624 | Sept. 18, 2015 |
|
|
New Topics Added to Our Website
 We recently added archived content from past issues of "Scleroderma Voice" magazine's "On Call" and "What's Up Doc?" columns on our website. These articles cover various topics and concerns that are common for people living with scleroderma.
Some of the topics include:
To view these and other past topics, click here >>
|
|
STAR Clinical Trial Now Enrolling Patients
If
you (or someone you know) have impaired function of the hands and
Raynaud Phenomenon due to scleroderma, you may be interested in the
STAR clinical trial. The STAR clinical trial is designed to study the
use of a patient’s own Adipose-Derived Regenerative Cells
(ADRCs), prepared using the investigational Celution® Device, in the
treatment of scleroderma affecting the hands and fingers. The study will
be conducted in patients who are currently on medical therapy and still
have impaired hand function and Raynaud’s phenomena. The STAR clinical
trial will enroll 80 patients in multiple centers in the United States.
Dinesh
Khanna, M.D., M.S., Director of University of Michigan Scleroderma Program
and principal investigator of the STAR trial shared his enthusiasm for hand management in
scleroderma, that affects over 90 percent of patients with scleroderma. Hand
symptoms are the leading cause of disability in this patient population,
more disabling than rheumatoid arthritis, and severely negatively
impact quality of life and work productivity. This study addresses this
unmet need. Details of the study can also be found on clinicaltrials.gov.
For more information, please visit www.startrial-us.com.
Additional Reading
Scleroderma Therapy Benefit Sustained at One Year Follow-Up
|
|
Biotechnology Firm Receives NIH Grant Support for Fibrosis Therapy
 PRESS RELEASE
NEW YORK, NY. September 9, 2015 –
iBio, Inc., a leader in plant-based biotechnology for
developing and manufacturing biopharmaceutical products, announced the
award of a grant to fund further development of its proprietary
therapeutic product for treatment of fibrotic diseases from the National
Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of
Health (NIH) under its Small Business Technology Transfer (STTR)
program. The Fast-Track award will support the work of principal
investigators Carol Feghali-Bostwick, Ph.D., of The Medical University
of South Carolina (MUSC) and Hal Padgett, Ph.D., of Novici Biotech LLC
(Novici) and their research teams. The funded project is entitled,
“Peptide Based Therapy for Lung Fibrosis.” The commercial sponsor of the
program is iBio, Inc.
Dr. Feghali-Bostwick is a member of the Scleroderma Foundation's Board of Directors.
Read the full press release here >>
|
|
Video: Don't Ignore Your Check Engine Light
It is easy for caregivers to focus on their loved ones living with
scleroderma and to ignore their own physical and emotional needs. Dr. Ginny Maril presented this
session at the 2015 National Patient Education Conference, which focused on
the caregiving experience and highlights the importance of self-care
while providing care for another. Learn to identify
personal strengths and challenges of your caregiving situations and what can be
done to maintain your own caregiving engines.
Watch the full session video now >>
|
|
|
|
|
Disclaimer: The Scleroderma Foundation in no way
endorses any drugs, treatments, clinical trials, or studies reported in the eLetter. Information is
provided to keep the readers informed. Because the manifestations and severity of scleroderma vary among individuals, personalized medical management is essential. Therefore, it is strongly recommended that all drugs and treatments be discussed with the reader’s physician(s) for proper evaluation and treatment.
|
 |
|
